{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:16:57Z","timestamp":1792725417044,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["DA054190"],"award-info":[{"award-number":["DA054190"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Med. Toxicol."],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13181-025-01104-6","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T18:27:51Z","timestamp":1762799271000},"page":"49-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Donovan Memorial Lecture: \u2018Fentanyl-Plus\u2019: A New Era of Fentanyl Polydrug Combinations in the North American Overdose Crisis"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-5477","authenticated-orcid":false,"given":"Daniel","family":"Ciccarone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"1104_CR1","doi-asserted-by":"crossref","unstructured":"Fessel JN et al. Into the epistemic void. In Inside Ethnography: Researchers Reflect on the Challenges of Reaching Hidden Populations. 2019. p. 120.","DOI":"10.2307\/j.ctvqmp20g.11"},{"key":"1104_CR2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.socscimed.2013.04.009","volume":"99","author":"L Messac","year":"2013","unstructured":"Messac L, et al. The good-enough science-and-politics of anthropological collaboration with evidence-based clinical research: four ethnographic case studies. Soc Sci Med. 2013;99:176\u201386.","journal-title":"Soc Sci Med"},{"issue":"1","key":"1104_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0955-3959(02)00219-0","volume":"14","author":"D Ciccarone","year":"2003","unstructured":"Ciccarone D. With both eyes open: notes on a disciplinary dialogue between ethnographic and epidemiological research among injection drug users. Int J Drug Policy. 2003;14(1):115\u20138.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"1104_CR4","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.16318","volume":"118","author":"J Friedman","year":"2023","unstructured":"Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race\/ethnicity and demographic trends in polysubstance Fentanyl overdose deaths in the United States, 2010\u20132021. Addiction. 2023;118(12):2477\u201385.","journal-title":"Addiction"},{"key":"1104_CR5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","volume":"71","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u20138.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1104_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350.","journal-title":"Curr Opin Psychiatry"},{"issue":"2","key":"1104_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2105\/AJPH.2007.131714","volume":"99","author":"A Van Zee","year":"2009","unstructured":"Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221\u20137.","journal-title":"Am J Public Health"},{"issue":"5","key":"1104_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamapsychiatry.2017.0163","volume":"74","author":"BK Madras","year":"2017","unstructured":"Madras BK. The surge of opioid use, addiction, and overdoses: responsibility and response of the US health care system. JAMA Psychiatr. 2017;74(5):441\u20132.","journal-title":"JAMA Psychiatr"},{"key":"1104_CR9","unstructured":"Meier B. Pain Killer: An empire of deceit and the origin of America\u2019s Opioid Epidemic. Random House Publishing Group; 2018."},{"issue":"1","key":"1104_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/pds.4558","volume":"28","author":"JA Lebin","year":"2019","unstructured":"Lebin JA, et al. Scoring the best deal: quantity discounts and street price variation of diverted oxycodone and oxymorphone. Pharmacoepidemiol Drug Saf. 2019;28(1):25\u201330.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1104_CR11","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.2810","volume":"15","author":"N Dasgupta","year":"2013","unstructured":"Dasgupta N, et al. Crowdsourcing black market prices for prescription opioids. J Med Internet Res. 2013;15(8):e2810.","journal-title":"J Med Internet Res"},{"key":"1104_CR12","doi-asserted-by":"crossref","unstructured":"Manchikanti L et al. Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American society of interventional pain physicians (ASIPP) guidelines. Pain Physician. 2017;20(2):S3\u2013S92.","DOI":"10.36076\/ppj.2017.s92"},{"issue":"2","key":"1104_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054496","volume":"8","author":"GJ Unick","year":"2013","unstructured":"Unick GJ, et al. Intertwined epidemics: National demographic trends in hospitalizations for heroin-and opioid-related overdoses, 1993\u20132009. PLoS ONE. 2013;8(2):e54496.","journal-title":"PLoS ONE"},{"issue":"2","key":"1104_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","volume":"25","author":"SG Mars","year":"2014","unstructured":"Mars SG, et al. Every \u2018never\u2019I ever said came true: transitions from opioid pills to heroin injecting. Int J Drug Policy. 2014;25(2):257\u201366.","journal-title":"Int J Drug Policy"},{"key":"1104_CR15","doi-asserted-by":"publisher","DOI":"10.7249\/RR3140","volume-title":"What america\u2019s users spend on illegal Drugs, 2006\u20132016","author":"G Midgette","year":"2019","unstructured":"Midgette G, et al. What america\u2019s users spend on illegal Drugs, 2006\u20132016. RAND Corporation: Santa Monica, California; 2019."},{"issue":"1","key":"1104_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/cid\/ciac543","volume":"76","author":"H Bradley","year":"2022","unstructured":"Bradley H, et al. Estimated number of people who inject drugs in the united states. Clin Infect Dis. 2022;76(1):96\u2013102.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1104_CR17","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJMe2406359","volume":"391","author":"D Ciccarone","year":"2024","unstructured":"Ciccarone D. Bending the overdose curve\u2014still not enough. N Engl J Med. 2024;391(11):1052\u20133.","journal-title":"N Engl J Med"},{"issue":"5","key":"1104_CR18","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/add.14474","volume":"114","author":"SG Mars","year":"2019","unstructured":"Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyls in the opioid street market: desired or imposed? Addiction. 2019;114(5):774\u201380.","journal-title":"Addiction"},{"key":"1104_CR19","doi-asserted-by":"crossref","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. 2017.","DOI":"10.1016\/j.drugpo.2017.06.010"},{"issue":"2","key":"1104_CR20","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/02791072.2017.1394508","volume":"50","author":"SG Mars","year":"2018","unstructured":"Mars SG, Ondocsin J, Ciccarone D. Sold as heroin: perceptions and use of an evolving drug in Baltimore, MD. J Psychoactive Drugs. 2018;50(2):167\u201376.","journal-title":"J Psychoactive Drugs"},{"key":"1104_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.drugpo.2017.06.004","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D, Ondocsin J, G Mars S. Heroin uncertainties: exploring users\u2019 perceptions of fentanyl-adulterated and-substituted \u2018heroin.\u2019 Int J Drug Policy. 2017;46:146\u201355.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1104_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12954-018-0232-z","volume":"15","author":"SG Mars","year":"2018","unstructured":"Mars SG, Ondocsin J, Ciccarone D. Toots, tastes and tester shots: user accounts of drug sampling methods for gauging heroin potency. Harm Reduct J. 2018;15(1):26. https:\/\/doi.org\/10.1186\/s12954-018-0232-z.","journal-title":"Harm Reduct J"},{"key":"1104_CR23","unstructured":"Hedegaard H, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 1999\u20132018. In NCHS Data Brief. 2020."},{"issue":"1","key":"1104_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.mcna.2021.08.010","volume":"106","author":"D Ciccarone","year":"2022","unstructured":"Ciccarone D, Shoptaw S. Understanding stimulant use and use disorders in a new era. Med Clin North Am. 2022;106(1):81.","journal-title":"Med Clin North Am"},{"key":"1104_CR25","unstructured":"Drug Enforcement Administration. 2025 National drug threat assessment. U.S. Department of Justice; 2025."},{"issue":"1","key":"1104_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00816-8","volume":"20","author":"J Ondocsin","year":"2023","unstructured":"Ondocsin J, et al. The motives and methods of methamphetamine and \u2018heroin\u2019co-use in West Virginia. Harm Reduct J. 2023;20(1):88.","journal-title":"Harm Reduct J"},{"key":"1104_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100238","volume":"11","author":"D Rosenblum","year":"2024","unstructured":"Rosenblum D, et al. Estimating changes in overdose death rates from increasing methamphetamine supply in Ohio: evidence from crime lab data. Drug Alcohol Depend Rep. 2024;11:100238.","journal-title":"Drug Alcohol Depend Rep"},{"key":"1104_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107779","volume":"208","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum D, Unick J, Ciccarone D. The rapidly changing US illicit drug market and the potential for an improved early warning system: evidence from Ohio drug crime labs. Drug Alcohol Depend. 2020;208:107779.","journal-title":"Drug Alcohol Depend"},{"key":"1104_CR29","doi-asserted-by":"crossref","unstructured":"Spencer MR et al. Drug overdose deaths involving xylazine: United States, 2018\u20132021. National Vital Statistics System, 2023(30).","DOI":"10.15620\/cdc:129519"},{"issue":"17","key":"1104_CR30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/jama.2024.15992","volume":"332","author":"JJ Palamar","year":"2024","unstructured":"Palamar JJ, Krotulski AJ. Medetomidine infiltrates the US illicit opioid market. JAMA. 2024;332(17):1425\u20136.","journal-title":"JAMA"},{"issue":"8","key":"1104_CR31","volume":"14","author":"SV Malayala","year":"2022","unstructured":"Malayala SV, et al. Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14(8):e28160.","journal-title":"Cureus"},{"issue":"2","key":"1104_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/29767342231214472","volume":"45","author":"JJ Carroll","year":"2024","unstructured":"Carroll JJ. Xylazine-Associated wounds and related health concerns among people who use drugs: reports from Front-Line health workers in 7 US States. Subst Use Addctn J. 2024;45(2):222\u201331.","journal-title":"Subst Use Addctn J"},{"issue":"1","key":"1104_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/ADM.0000000000001245","volume":"18","author":"R McFadden","year":"2024","unstructured":"McFadden R, et al. Xylazine-associated wounds: clinical experience from a low-barrier wound care clinic in Philadelphia. J Addict Med. 2024;18(1):9\u201312.","journal-title":"J Addict Med"},{"key":"1104_CR34","doi-asserted-by":"crossref","unstructured":"Bedard ML et al. Xylazine and fentanyl co-administration delays wound healing in mice. bioRxiv, 2025: p. 2025.06. 18.660449.","DOI":"10.1101\/2025.06.18.660449"},{"key":"1104_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.104830","volume":"142","author":"D Ciccarone","year":"2025","unstructured":"Ciccarone D, et al. Tranq burn: exploring the etiology of xylazine-related soft tissue injuries. Int J Drug Policy. 2025;142:104830.","journal-title":"Int J Drug Policy"},{"key":"1104_CR36","doi-asserted-by":"publisher","first-page":"p109398","DOI":"10.1016\/j.drugalcdep.2022.109398","volume":"234","author":"JJ Palamar","year":"2022","unstructured":"Palamar JJ, et al. Trends in seizures of powders and pills containing illicit Fentanyl in the united States, 2018 through 2021. Drug Alcohol Depend. 2022;234:p109398.","journal-title":"Drug Alcohol Depend"},{"key":"1104_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104417","volume":"138","author":"JJ Palamar","year":"2025","unstructured":"Palamar JJ, et al. National and regional trends in fentanyl seizures in the united States, 2017\u20132023. Int J Drug Policy. 2025;138:104417.","journal-title":"Int J Drug Policy"},{"key":"1104_CR38","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell J, et al. Drug overdose deaths with evidence of counterfeit pill use\u2014United States, July 2019\u2013December 2021. MMWR. Morbidity and Mortality Weekly Report; 2023. p. 72.","DOI":"10.15585\/mmwr.mm7235a3"},{"issue":"21","key":"1104_CR39","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1001\/jama.2024.6161","volume":"331","author":"RS Wightman","year":"2024","unstructured":"Wightman RS, et al. Substances in counterfeit prescription pills seized by law enforcement, 2017\u20132022. JAMA. 2024;331(21):1860\u20132.","journal-title":"JAMA"},{"issue":"14","key":"1104_CR40","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1001\/jama.2022.2847","volume":"327","author":"J Friedman","year":"2022","unstructured":"Friedman J, et al. Trends in drug overdose deaths among US adolescents, January 2010 to June 2021. JAMA. 2022;327(14):1398\u2013400.","journal-title":"JAMA"},{"issue":"50","key":"1104_CR41","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.15585\/mmwr.mm7150a2","volume":"71","author":"LJ Tanz","year":"2022","unstructured":"Tanz LJ, et al. Drug overdose deaths among persons aged 10\u201319 years - United States, July 2019-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(50):1576\u201382.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1104_CR42","doi-asserted-by":"publisher","DOI":"10.17269\/s41997-024-00990-7","author":"S Tobias","year":"2025","unstructured":"Tobias S, et al. Novel adulterants in unregulated opioids and their associations with adverse events. Can J Public Health. 2025;116:356\u2013363. https:\/\/doi.org\/10.17269\/s41997-024-00990-7","journal-title":"Can J Public Health"},{"key":"1104_CR43","volume-title":"Smack: heroin and the American City","author":"EC Schneider","year":"2013","unstructured":"Schneider EC. Smack: heroin and the American City. Philadelphia: University of Pennsylvania; 2013."},{"key":"1104_CR44","doi-asserted-by":"crossref","unstructured":"Farber D. Crack: rock Cocaine, street capitalism, and the decade of greed. Cambridge University Press; 2019.","DOI":"10.1017\/9781108349055"},{"issue":"1","key":"1104_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/ADM.0000000000000695","volume":"15","author":"S Wakeman","year":"2021","unstructured":"Wakeman S, Flood J, Ciccarone D. Rise in presence of methamphetamine in oral fluid toxicology tests among outpatients in a large healthcare setting in the Northeast. J Addict Med. 2021;15(1):85\u20137.","journal-title":"J Addict Med"},{"issue":"1","key":"1104_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-00976-1","volume":"21","author":"S Mars","year":"2024","unstructured":"Mars S, et al. The influence of transformations in supply on methamphetamine initiation among people injecting opioids in the United States. Harm Reduct J. 2024;21(1):57.","journal-title":"Harm Reduct J"},{"key":"1104_CR47","unstructured":"Ciccarone D. No moral panic: public health responses to illicit Fentanyls. DePaul L Rev. 2022;70(2):229\u2013244."},{"key":"1104_CR48","unstructured":"Humphreys K, Caulkins JP. Destigmatizing drug use has been a profound mistake. In The Atlantic; 2023."},{"issue":"2","key":"1104_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622\u20131920622.","journal-title":"JAMA Netw Open"},{"key":"1104_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.","journal-title":"BMJ"},{"issue":"5","key":"1104_CR51","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/add.13265","volume":"111","author":"SM Bird","year":"2016","unstructured":"Bird SM, et al. Effectiveness of scotland\u2019s national naloxone programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. Addiction. 2016;111(5):883\u201391.","journal-title":"Addiction"},{"key":"1104_CR52","doi-asserted-by":"publisher","first-page":"102536","DOI":"10.1016\/j.drugpo.2019.07.031","volume":"75","author":"T Townsend","year":"2020","unstructured":"Townsend T, et al. Cost-effectiveness analysis of alternative Naloxone distribution strategies: first responder and Lay distribution in the united States. Int J Drug Policy. 2020;75:102536.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1104_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","volume":"158","author":"P Coffin","year":"2013","unstructured":"Coffin P, Sullivan S. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1104_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0303403","volume":"19","author":"D Ciccarone","year":"2024","unstructured":"Ciccarone D, et al. Innovation and adaptation: the rise of a Fentanyl smoking culture in San Francisco. PLoS ONE. 2024;19(5):e0303403.","journal-title":"PLoS ONE"},{"key":"1104_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111419","volume":"263","author":"G Karandinos","year":"2024","unstructured":"Karandinos G, et al. Decrease in injection and rise in smoking and snorting of heroin and synthetic opioids, 2000\u20132021. Drug Alcohol Depend. 2024;263:111419.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"1104_CR56","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/j.1360-0443.1997.tb02927.x","volume":"92","author":"J Strang","year":"1997","unstructured":"Strang J, Griffiths P, Gossop M. Heroin smoking by \u2018chasing the dragon\u2019: origins and history. Addiction. 1997;92(6):673\u201383.","journal-title":"Addiction"},{"key":"1104_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111053","volume":"255","author":"CE Megerian","year":"2024","unstructured":"Megerian CE, et al. Health risks associated with smoking versus injecting Fentanyl among people who use drugs in California. Drug Alcohol Depend. 2024;255:111053.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"1104_CR58","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/add.16740","volume":"120","author":"G Karandinos","year":"2025","unstructured":"Karandinos G, Unick J, Ciccarone D. Mortality risk among individuals who smoke opioids compared with those who inject: a propensity score-matched cohort analysis of united states national treatment data. Addiction. 2025;120(5):1040\u20135.","journal-title":"Addiction"},{"issue":"2","key":"1104_CR59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11524-024-00852-0","volume":"101","author":"AR Bazazi","year":"2024","unstructured":"Bazazi AR, et al. Overdose from unintentional fentanyl use when intending to use a non-opioid substance: an analysis of medically attended opioid overdose events. J Urban Health. 2024;101(2):245\u201351.","journal-title":"J Urban Health"},{"key":"1104_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103169","volume":"93","author":"MK Laing","year":"2021","unstructured":"Laing MK, et al. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: preliminary results from a community drug checking program using point-of-care and confirmatory methods. Int J Drug Policy. 2021;93:103169.","journal-title":"Int J Drug Policy"},{"key":"1104_CR61","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.06.020","volume":"190","author":"KW Tupper","year":"2018","unstructured":"Tupper KW, et al. Initial results of a drug checking pilot program to detect Fentanyl adulteration in a Canadian setting. Drug Alcohol Depend. 2018;190:242\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1104_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11243-4","volume":"21","author":"B Wallace","year":"2021","unstructured":"Wallace B, et al. The potential impacts of community drug checking within the overdose crisis: qualitative study exploring the perspective of prospective service users. BMC Public Health. 2021;21(1):1156.","journal-title":"BMC Public Health"},{"issue":"11","key":"1104_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20115999","volume":"20","author":"J Ondocsin","year":"2023","unstructured":"Ondocsin J, et al. Insights from drug checking programs: practicing bootstrap public health whilst tailoring to local drug user needs. Int J Environ Res Public Health. 2023;20(11):5999.","journal-title":"Int J Environ Res Public Health"},{"key":"1104_CR64","doi-asserted-by":"publisher","DOI":"10.1097\/PHH.0000000000001581","author":"TC Green","year":"2022","unstructured":"Green TC, et al. Implementation and uptake of the Massachusetts drug supply data stream: a statewide public health-public safety partnership drug checking program. J Public Health Manag Pract. 2022;28:S347\u2013S354. https:\/\/doi.org\/10.1097\/PHH.0000000000001581","journal-title":"J Public Health Manag Pract"},{"key":"1104_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110985","volume":"252","author":"KD Wagner","year":"2023","unstructured":"Wagner KD, et al. Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services. Drug Alcohol Depend. 2023;252:110985.","journal-title":"Drug Alcohol Depend"},{"key":"1104_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108976","volume":"228","author":"L Karch","year":"2021","unstructured":"Karch L, et al. Results from a mobile drug checking pilot program using three technologies in Chicago, IL, USA. Drug Alcohol Depend. 2021;228:108976.","journal-title":"Drug Alcohol Depend"},{"key":"1104_CR67","doi-asserted-by":"crossref","unstructured":"Shover CL et al. High variation in purity of consumer-level illicit fentanyl samples in Los Angeles, 2023\u20132025. medRxiv, 2025: p. 2025.06.27.25330446.","DOI":"10.1101\/2025.06.27.25330446"},{"issue":"1","key":"1104_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00921-8","volume":"21","author":"JC Halifax","year":"2024","unstructured":"Halifax JC, et al. Testing the test strips: laboratory performance of fentanyl test strips. Harm Reduct J. 2024;21(1):14.","journal-title":"Harm Reduct J"},{"key":"1104_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103147","volume":"92","author":"MK Reed","year":"2021","unstructured":"Reed MK. \u201cI probably got a minute\u201d: Perceptions of fentanyl test strip use among people who use stimulants. Int J Drug Policy. 2021;92:103147.","journal-title":"Int J Drug Policy"},{"key":"1104_CR70","unstructured":"Bmore POWER. 2025 [cited 2025 August 13]; Available from: https:\/\/goslow.org\/"},{"key":"1104_CR71","doi-asserted-by":"crossref","unstructured":"Clinical Guideline Committee Members, et al. The ASAM\/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024;18(1S):1\u201356.","DOI":"10.1097\/ADM.0000000000001299"}],"container-title":["Journal of Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-025-01104-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13181-025-01104-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13181-025-01104-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T16:02:46Z","timestamp":1769443366000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13181-025-01104-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1104"],"URL":"https:\/\/doi.org\/10.1007\/s13181-025-01104-6","relation":{},"ISSN":["1556-9039","1937-6995"],"issn-type":[{"value":"1556-9039","type":"print"},{"value":"1937-6995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Daniel Ciccarone reports the following relevant financial relationships during the past 60 months: 1, he is a scientific advisor to Celero Systems and 2, he has been retained as an expert witness in ongoing prescription opioid litigation by Motley Rice, LLP.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"He reports the following non-financial competing interest: he is voluntary Medical Director for Remedy Alliance.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}